Lymphoid malignancies are a group of highly heterogeneous diseases frequently
associated with constitutive activation of the nuclear factor kappa B (NF-κB) signaling …

Multiple myeloma is the second most common malignant hematologic malignancy which
evolved different strategies for immune escape from the host immune surveillance and drug …

Multiple myeloma (MM) is a blood cell neoplasm characterized by excessive production of
malignant monoclonal plasma cells (activated B lymphocytes) by the bone marrow, which …

With the advent of novel, highly effective therapies for multiple myeloma (MM), classical
serologic monitoring appears insufficient for response assessment and prediction of relapse …

Background Immunotherapies targeting CD38 have demonstrated salient efficacy in
relapsed/refractory multiple myeloma (MM). However, loss of CD38 antigen and outgrowth …

Although treatment options for multiple myeloma (MM) are rapidly evolving, there still remain
difficult-to-treat situations, especially in relapsed and/or refractory (r/r) disease. When …

The Lymphocyte-Activation Protein 3 (LAG-3) inhibitory receptor is expressed on regulatory
plasma cells (PCs). Micro-environmental cells that express LAG-3 were found to be …

Multiple myeloma (MM) is the second most prevalent hematologic malignancy which
remains uncurable. Numerous drugs have been discovered to inhibit MM cells. Indisulam …

Noncoding RNAs (ncRNAs) constitute a class of nucleic acid molecules within cells that do
not encode proteins but play important roles in regulating gene expression, maintaining …

Multiple myeloma is the second most commonly diagnosed hematologic malignancy. As an
incurable disease, the molecular mechanisms underlying its many aspects remain unclear …